Top story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Read full story

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Drugs.com - New Drug Approvals
Wed, 30 Apr 2025
Read more

Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application for Elamipretide

Drugs.com - New Drug Applications
Tue, 29 Apr 2025
Read more

Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Drugs.com - New Drug Approvals
Wed, 26 Mar 2025
Read more

FDA Approves Vykat XR (diazoxide choline) to Treat Hyperphagia in Prader-Willi Syndrome

Drugs.com - New Drug Approvals
Wed, 26 Mar 2025
Read more

Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma

Drugs.com - New Drug Applications
Wed, 26 Feb 2025
Read more

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia

Drugs.com - New Drug Applications
Wed, 19 Feb 2025
Read more

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

PharmaProLearn News
Wed, 29 Jan 2025
Read more

Saol Therapeutics Announces FDA Acceptance of New Drug Application for SL1009 for Treatment of Pyruvate Dehydrogenase Complex Deficiency

PharmaProLearn News
Tue, 28 Jan 2025
Read more

Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia

PharmaProLearn News
Wed, 27 Nov 2024
Read more